ログイン

SUMMATIVE EXAM #4

SUMMATIVE EXAM #4
100問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    The growth factor that is produced in the kidney/liver and INDUCES GROWTH AND DIFFERENTIATION OF COMMITTED MEGAKARYOCYTE PROGENITORS is: A. IL-3 B. IL-6 C. IL-11 D. TPO

    D. TPO

  • 2

    Which of the following is (are) true of ENDOREDUPLICATION? A. Duplicates DNA without cell division B. Results in cells with ploidy values of 4n, 8n, 16n and 32n C. Is unique to the megakaryocytic type of blood cell D. All of the above

    D. All of the above

  • 3

    The megakaryocyte progenitor that undergoes endomitosis is: A. MK-I B. BFU-Meg C. CFU-Meg D. LD-CFU-Meg

    D. LD-CFU-Meg

  • 4

    The cellular ultrastructural component unique to the platelet is the: A. Cytoplasmic membrane B. Glycocalyx C. Mitochondrion D. Microtubule

    B. Glycocalyx

  • 5

    Which of the following is not a characteristic of platelets? A. The presence of a nucleus B. Size of 2 to 4 µm C. Cytoplasm is light blue with fine red-purple granules D. A discoid shape as an inactive cell

    A. The presence of a nucleus

  • 6

    Choose the INCORRECT statement regarding storage granules related to hemostasis in the mature platelet. A. Alpha granules contain platelet factor 4, betathromboglobulin, and platelet-derived growth factor. B. Alpha granules contain platelet fibrinogen and von Willebrand factor. C. Dense bodies contain serotonin n ADP. D. Lysosomes contain actomyosin, myosin, and flamin

    D. Lysosomes contain actomyosin, myosin, and flamin

  • 7

    Platelet aggregation will occur with the end production of: A. Cyclooxygenase B. Arachidonic acid C. Prostacyclin D. Thromboxane A2

    D. Thromboxane A2

  • 8

    Reticulated platelets can be enumerated in peripheral blood to detect: A. Impaired production in disease states B. Abnormal organelles associated with diseases such as leukemia C. Increased platelet production in response to need D. Inadequate rates of membrane cholesterol exchange with the plasma

    C. Increased platelet production in response to need

  • 9

    At all times, approximately ____ of the total number of platelets are in the systemic circulation. A. One-fourth B. One-third C. One-half D. Two-thirds

    D. Two-thirds

  • 10

    The reference range of platelets in the systemic circulation is: A. 50 to 120 x 109/L B. 100 to 200 x 109/L C. 150 to 350 x 109/L D. 150 to 400 x 109/L

    D. 150 to 400 x 109/L

  • 11

    Agents that are capable of aggregating platelets include: A. Collagen B. Thrombin C. Serotonin D. All of the above

    D. All of the above

  • 12

    In measuring platelet aggregation, platelet-rich plasma can be treated with ___ to aggregate platelets. A. Saline B. Collagen C. Epinephrine D. Both B and C

    D. Both B and C

  • 13

    What coagulation plasma protein should be assayed when platelets fail to aggregate properly? A. Factor VIII B. Fibrinogen C. Thrombin D. Factor X

    B. Fibrinogen

  • 14

    Aspirin ingestion has the following hemostatic effect in a normal person. A. Prolongs the bleeding time B. Prolongs the clotting time C. Inhibits factor VIII D. Has no effect

    A. Prolongs the bleeding time

  • 15

    The bleeding time test measures: A. Ability of platelets to stick together B. Platelet adhesion and aggregation of locally injured vascular subendothelium C. Quantity and quality of platelets D. Antibodies against platelets

    B. Platelet adhesion and aggregation of locally injured vascular subendothelium

  • 16

    The clot retraction test is: A. Visible reaction to the activation of platelet actomyosin (thrombosthenin) B. Reflection of the quantity and quality of platelets and other factors C. Measurement of the ability of platelets to stick to glass D. Measurement of the cloudiness of blood

    B. Reflection of the quantity and quality of platelets and other factors

  • 17

    Wiskott-Aldrich syndrome is characterized by: A. Giant platelets B. Smallest platelets seen C. Large platelets D. Absence of platelets

    B. Smallest platelets seen

  • 18

    May-Hegglin anomaly is characterized by: A. Giant platelets B. Smallest platelets seen C. Large platelets D. Absence of platelets

    C. Large platelets

  • 19

    Bernard-Soulier syndrome is characterized by: A. Giant platelets B. Smallest platelets seen C. Large platelets D. Absence of platelets

    A. Giant platelets

  • 20

    Hereditary platelet dysfunction can be caused by: A. Aspirin B. von Willebrand’s disease C. Uremia D. Factor V deficiency

    B. von Willebrand’s disease

  • 21

    Which of the following parameters can be abnormal in classic von Willebrand’s disease type I? A. Bleeding time B. PT C. Platelet count D. All of the above

    A. Bleeding time

  • 22

    The most common for of von Willebrand’s disease is: A. Type I B. Type II C. Type III D. All have about the same incidence

    A. Type I

  • 23

    When comparing von Willebrand’s disease and Glanzmann’s thrombasthenia, Glanzmann’s thrombasthenia will demonstrate: A. Absent ADP B. Normal clot retraction C. Abnormal ristocetin aggregation D. Abnormal release of ADP

    A. Absent ADP

  • 24

    Acquired platelet dysfunction can be caused by: A. Aspirin B. Von Willebrand’s disease C. Uremia D. Factor V deficiency

    C. Uremia

  • 25

    Thrombin: A. III B. XII C. VIII D. IIa

    D. IIa

  • 26

    Tissue thromboplastin: A. III B. XII C. VIII D. IIa

    A. III

  • 27

    Anti-hemophilic factor: A. III B. XII C. VIII D. IIa

    C. VIII

  • 28

    Hageman factor: A. III B. XII C. VIII D. IIa

    B. XII

  • 29

    The extrinsic pathway of coagulation is triggered by the entry of ___ into the circulation. A. Membrane lipoproteins (phospholipoproteins) B. Tissue thromboplastin C. Calcium D. Factor VII

    B. Tissue thromboplastin

  • 30

    The intrinsic pathway of coagulation begins with the activation of ____ in the early stage. A. Factor II B. Factor I C. Factor XII D. Factor V

    C. Factor XII

  • 31

    The final common pathway of the intrinsic-extrinsic pathway is: A. Factor X activation B. Factor II activation C. Factor I activation D. Factor XII activation

    A. Factor X activation

  • 32

    Fibrinogen is converted to thrombin monomers by: A. Prothrombin B. Thrombin C. Calcium ions D. Factor XIIIa

    B. Thrombin

  • 33

    The fibrinogen group of coagulation factors: A. Known to increase during pregnancy B. Known to increase in conditions of inflammation C. Known to increase subsequent to the use of oral contraceptives D. All of the above

    D. All of the above

  • 34

    A pregnant woman has routine coagulation testing performed. PT and APTT are normal. Her fibrinogen level is elevated at 450 (reference range 150 to 350) due to acute phase reactants during pregnancy. The other factor that may be elevated due to this is: A. FVII B. FVIII C. FXI D. FXIII

    B. FVIII

  • 35

    Vitamin K dependent coagulation factor: A. II B. V C. VIII D. XIII

    A. II

  • 36

    Unique characteristic associated with associated with a deficiency of Factor XII is: A. Frequent nose bleeds B. No history of bleeding C. Common factor deficiency D. Decreased risk of forming blood clots

    B. No history of bleeding

  • 37

    Factor XII deficiency is associated with: A. Bleeding episodes B. Epistaxis C. Decreased risk of thrombosis D. Increased risk of thrombosis

    D. Increased risk of thrombosis

  • 38

    What happens if a coagulation specimen collection tube is underfilled? A. The specimen clots and is useless B. The specimen is hemolyzed and is useless C. Clot-based test results are falsely prolonged D. Chromogenic test results are falsely decreased

    C. Clot-based test results are falsely prolonged

  • 39

    Most coagulation testing must be performed on PPP, which is plasma with a platelet count less than: A. 1000/µL B. 10,000/µL C. 100,000/µL D. 1,000,000/µL

    B. 10,000/µL

  • 40

    The function of thromboplastin in the prothrombin test is to provide _____ to the assay. A. Kaolin B. Fibrinogen C. Phospholipoprotein D. Thrombin

    C. Phospholipoprotein

  • 41

    An abnormally prolonged APTT may indicate: A. Severe depletion of fibrinogen B. Presence of circulating anticoagulant C. Factor VIII deficiency D. All of the above

    D. All of the above

  • 42

    Neither the APTT nor the PT detects a deficiency of: A. Platelet factor 3 B. Factor VII C. Factor VIII D. Factor IX

    A. Platelet factor 3

  • 43

    Which laboratory test is affected by heparin therapy? A. Thrombin time B. Fibrinogen assay C. Protein C assay D. Protein S assay

    A. Thrombin time

  • 44

    The test reagent in APTT contains which of the following substance(s)? 1. Citrated plasma 2. Calcium ions 3. Tissue thromboplastin 4. Phospholipids A. 1, 2 and 3 are correct B. 1 and 3 are correct C. 2 and 4 are correct D. Only 4 is correct

    C. 2 and 4 are correct

  • 45

    The test reagent in PT contains which of the following substance(s)? 1. Calcium ions 2. Kaolin 3. Tissue thromboplastin 4. Celite A. 1, 2 and 3 are correct B. 1 and 3 are correct C. 2 and 4 are correct D. Only 4 is correct

    B. 1 and 3 are correct

  • 46

    If a child ingested rat poison, which of the following tests should be performed to test the effect of the poison on the child’s coagulation mechanism? A. aPTT B. PT C. Fibrinogen assay D. Thrombin time

    B. PT

  • 47

    A patient on therapeutic warfarin will most likely have a(n): A. Normal PT/INR, increased APTT, prolonged bleeding time, low platelet count B. Increased PT/INR, increased APTT, normal bleeding time, normal platelet count C. Normal PT/INR, normal APTT, normal bleeding time, normal platelet count D. Increased PT/INR, normal APTT, prolonged bleeding time, low platelet count

    B. Increased PT/INR, increased APTT, normal bleeding time, normal platelet count

  • 48

    If heparin therapy is initiated in a patient, a decreased anticoagulant response can be caused by decreased levels of: A. Platelet factor 3 B. Platelet factor 4 C. Anti-thrombin D. Factor XIII

    B. Platelet factor 4 - TURGEON C. Anti-thrombin - RIGHT ANSWER

  • 49

    Heparin-induced thrombocytopenia (HIT) results from: A. Antibodies to heparin B. Antibodies to platelets C. Antibodies to PF4 D. Antibodies to heparin-PF4 complex

    D. Antibodies to heparin-PF4 complex

  • 50

    A modification of which procedure can be used to measure fibrinogen? A. PT B. APTT C. Thrombin time D. Fibrin degradation products

    C. Thrombin time

  • 51

    In the Clauss fibrinogen method, the time to clot formation in plasma is measured after the addition of: A. Calcium B. Thrombin C. Phospholipids D. Kaolin

    B. Thrombin

  • 52

    Which test result would be normal in a patient with dysfibrinogenemia? A. Thrombin time B. APTT C. PT D. Immunologic fibrinogen level

    D. Immunologic fibrinogen level

  • 53

    A standard blue-top tube filled appropriately (with 4.5 mL blood) was submitted to the laboratory for preoperative PT and APTT testing. The results of both tests were elevated. § The patient’s PT and APTT from the previous day were within normal limits, and he is not on heparin therapy. Which is the most appropriate first step to investigate the abnormal results? A. Report the result as obtained B. Perform a mixing study C. Check the sample for a clot D. Report the APTT only

    C. Check the sample for a clot

  • 54

    A fresh blood sample was sent to the laboratory at 8:00 a.m. for a PT test. At 4:00 p.m., the doctor requested an APTT test to be done on the same sample. What should the technologist do? A. Rerun APTT on the 8:00 a.m. sample and report the result B. Request a new sample for APTT C. Run APTT in duplicate and report the average D. Mix the patient plasma with normal plasma and run the APTT

    B. Request a new sample for APTT

  • 55

    A plasma sample submitted to the lab for PT testing has been stored for 25 hours at 4°C. The PT result is shortened. What is the most probable cause? A. Factor VII deficiency B. Activation of factor VII due to exposure to cold temperature C. Lupus inhibitor D. Factor X inhibitor

    B. Activation of factor VII due to exposure to cold temperature

  • 56

    An abnormal APTT caused by a pathological circulating anticoagulant is: A. Corrected with factor VIII–deficient plasma B. Corrected with factor IX–deficient plasma C. Corrected with normal plasma D. Not corrected with normal plasma

    D. Not corrected with normal plasma

  • 57

    Which of the following abnormalities is consistent with the presence of lupus anticoagulant? A. Decreased APTT/bleeding complications B. Prolonged APTT/thrombosis C. Prolonged APTT/thrombocytosis D. Thrombocytosis/thrombosis

    B. Prolonged APTT/thrombosis

  • 58

    What clotting factors (cofactors) are inhibited by protein S? A. V and X B. Va and VIIIa C. VIII and IX D. VIII and X

    B. Va and VIIIa

  • 59

    A THROMBOSIS MARKER that has shown high sensitivity for disseminated intravascular coagulation (DIC) is: A. Thrombin-antithrombin (TAT) B. Prothrombin fragment 1.2 (PF1.2) C. Fibrinopeptide A (FPA) D. D-dimer (D-D)

    D. D-dimer (D-D)

  • 60

    The APTT results are not elevated in a patient receiving heparin. Which of the following factors may be associated with the lack of response to heparin therapy in this patient? A. Protein C deficiency B. Antithrombin deficiency C. Protein S deficiency D. Factor VIII deficiency

    B. Antithrombin deficiency

  • 61

    Which of the following is the appropriate principle or description of the antithrombin assay? A. In the presence of heparin, thrombin is neutralized B. Measures the time required to generate thrombin and fibrin polymers via the intrinsic pathway C. Measures inhibitors of specific factors D. An in vivo measurement of platelet adhesion and aggregation on locally injured vascular subendothelium

    A. In the presence of heparin, thrombin is neutralized

  • 62

    . The FIRST step in the determination of functional antithrombin III (AT III) is to: A. Neutralize plasma antithrombin B. Neutralize thrombin with test plasma C. Incubate plasma with anti-AT III D. Precipitate AT III with plasma

    B. Neutralize thrombin with test plasma

  • 63

    Which of the following is considered to be an advantage of the mechanical end-point detection methodology? A. It is not affected by lipemia in the test sample B. It has the ability to provide a graph of clot formation C. It can incorporate multiple wavelengths into a single testing sequence D. It can measure proteins that do not have fibrin formation as the end-point

    A. It is not affected by lipemia in the test sample

  • 64

    The fibrometer relies on the principle of: A. Clot elasticity B. Fibrin adhesion C. Conduction or impedance of an electrical current by fibrin D. Changes in optical density

    C. Conduction or impedance of an electrical current by fibrin

  • 65

    In the photo-optical method, the change in light transmission versus the ____ is used to determine the activity of coagulant factors or stages. A. Amount of patient’s plasma B. Amount of test reagent C. Time D. Temperature

    C. Time

  • 66

    Which clinical or specimen condition will produce an increased PCV test result? A. Splenectomy B. Rouleaux formation C. Polycythemia D. Hemolytic anemia crisis

    C. Polycythemia

  • 67

    Which of the following blood specimen conditions would NOT cause a falsely elevated concentration with a manually performed cyanamethemoglobin determination? A. Lipemia B. Extremely elevated WBC count C. Hemoglobin S D. Hemoglobin F

    D. Hemoglobin F

  • 68

    If an MCHC result of 40 g/dL is discovered in a patient’s instrumentation printout, what is the possible cause? A. Increased RDW B. Hypochromic RBC C. Agglutinated RBCs D. Increased number of RBC fragments

    C. Agglutinated RBCs

  • 69

    What hematology test is useful in monitoring the production of erythrocytes? A. Total iron binding capacity B. Ferritin level C. Reticulocyte count D. Hemoglobin

    C. Reticulocyte count

  • 70

    On a Wright-stained peripheral blood smear, stress or shift reticulocytes are: A. Smaller than normal reticulocytes B. About the same size as normal reticulocytes C. Larger than normal reticulocytes D. Noticeable because of a decreased blue tint

    C. Larger than normal reticulocytes

  • 71

    Reticulocytes can be detected using ___ stain. A. New methylene blue B. Thiazole orange C. Propidium iodide D. Both A and B

    D. Both A and B

  • 72

    The normal range of reticulocytes in adults is: A. 0 to 0.5% B. 0.5 to 1% C. 0.5 to 2.5% D. 1.5 to 2.5%

    C. 0.5 to 2.5%

  • 73

    The refence value for reticulocyte count in a newborn infant is: A. Up to 13 mm per hour B. 2.5 to 6.5% C. 150 to 450 x 109 /L D. 36 to 45%

    B. 2.5 to 6.5%

  • 74

    What clinical or specimen condition will produce an increased reticulocyte count test result? A. Splenectomy B. Rouleaux formation C. Polycythemia D. Hemolytic anemia crisis

    D. Hemolytic anemia crisis

  • 75

    What clinical condition will produce a decreased reticulocyte count? A. Polycythemia vera B. Acute leukemias C. Megaloblastic anemia D. Viral infection

    C. Megaloblastic anemia

  • 76

    If a male patient has a reticulocyte count of 5.0% and a packed cell volume of 0.45 L/L, what is his corrected reticulocyte count? A. 2.5% B. 4.5% C. 5.0% D. 10%

    C. 5.0%

  • 77

    If a patient has a reticulocyte count of 7% and an Hct of 20%, what is the corrected reticulocyte count? A. 1.4% B. 3.1% C. 3.5% D. 14%

    B. 3.1%

  • 78

    If a male patient has a reticulocyte count of 6.0% and a packed cell volume of 45%, what is his RPI? A. 1.5 B. 3.0 C. 4.5 D. 6.0

    D. 6.0

  • 79

    Given the following values, calculate the RPI: § Observed reticulocyte count = 6% § HCT = 30% A. 2 B. 3 C. 4 D. 5

    A. 2

  • 80

    The ESR is a nonspecific indicator of disease with increased sedimentation of erythrocytes in: A. Infections B. Inflammations C. Tissue necrosis D. All of the above

    D. All of the above

  • 81

    The reference value for the Westergren ESR method for adult male less than 50 years of age is: A. 0 to 10 mm/hour B. 2.5 to 6.0% C. 150 to 450 x 109/L D. 36 to 35%

    A. 0 to 10 mm/hour

  • 82

    The reference value for the Westergren ESR method (adult male over 50 years) is: A. Up to 15 mm/hour B. 2.5 to 6% C. 150 to 450 x 109 /L D. 36 to 45%

    A. Up to 15 mm/hour

  • 83

    Which clinical or specimen condition will produce an increased Westergren ESR method test result? A. Splenectomy B. Rouleaux formation C. Polycythemia D. Hemolytic anemia crisis

    B. Rouleaux formation

  • 84

    Which clinical or specimen condition will produce an decreased Westergren ESR method test result? A. Polycythemia vera B. Acute leukemias C. Megaloblastic anemia D. Viral infection

    A. Polycythemia vera

  • 85

    What clinical or specimen condition will produce an increased total leukocyte count? A. Active allergies B. Immediate hypersensitivity reactions C. Inflammation D. Lipemic blood specimen

    C. Inflammation

  • 86

    What clinical condition will produce an increased value of neutrophils? A. Invasive parasites B. Bacterial infections C. Viral infections D. Tuberculosis

    B. Bacterial infections

  • 87

    What clinical condition will produce an increased value of eosinophils? A. Invasive parasites B. Bacterial infections C. Viral infections D. Tuberculosis

    A. Invasive parasites

  • 88

    What clinical condition will produce an increased value of lymphocytes? A. Invasive parasites B. Bacterial infections C. Viral infections D. Tuberculosis

    C. Viral infections

  • 89

    A normal blood smear should have no more than approximately ____ (maximum) number of platelets per OIF in an area where the erythrocytes are just touching each other. A. 10 B. 15 C. 20 D. 25

    C. 20

  • 90

    If small blood clot exists in an anticoagulated blood specimen, which blood cell parameter will be affected the most? A. Leukocyte count B. Erythrocyte count C. Platelet count D. Microhematocrit

    C. Platelet count

  • 91

    If platelet clumping was observed by direct observation of a stained peripheral blood smear and/or indicated by the output of an automated instrument, what corrective action can be taken? A. Retrieve the patient specimen and prepare a new blood smear B. Retrieve the patient specimen and warm it up to 37 o C for 15 minutes and reanalyze C. Recollect a new EDTA-anticoagulated specimen and promptly examine the platelets D. Recollect a new citrate anticoagulated specimen and reexamine the platelets.

    D. Recollect a new citrate anticoagulated specimen and reexamine the platelets

  • 92

    The recommended cleaner for removing oil from objectives is: A. 70% alcohol or lens cleaner B. Xylene C. Water D. Benzene

    A. 70% alcohol or lens cleaner

  • 93

    Which of the following is not a benefit of laboratory instrumentation to the hematology laboratory? A. Produces faster results from specimens B. Reduced cost on rarely performed procedures C. Less variation in technique from technologist to technologist D. Increased accuracy because data are collected on more cells counted or analyzed

    B. Reduced cost on rarely performed procedures

  • 94

    Sometimes used in conjunction with DC: A. Electronic impedance B. Optical scatter C. Radiofrequency D. None of these

    C. Radiofrequency

  • 95

    The abbreviation LASER stands for: A. Light associated stimulated emission of radiation B. Largely amplified by stimulated emission of radiation C. Light amplified by stimulated emission of radiation D. Liquid amplified by stimulated emission of radiation

    C. Light amplified by stimulated emission of radiation

  • 96

    Major systems in a flow cytometer include all of the following, EXCEPT: A. Fluidics B. Optics C. Computerized electronics D. Gating

    D. Gating

  • 97

    The restriction of data analysis to one cell population is accomplished by: A. Amplification B. Gating C. Compensatory monitoring D. Data limitation

    B. Gating

  • 98

    Which of the following can be an application of flow cytometry? A. Screening erythrocytes for malaria B. Counting reticulocytes C. Quantitation of T and B cells D. All of the above

    D. All of the above

  • 99

    The major application of flow cytometry is: A. Determining cell size and granularity B. Sorting of cells and cellular identification using monoclonal antibodies C. Treating cancer cells and identifying specific virus types D. Counting leukocytes and platelets

    B. Sorting of cells and cellular identification using monoclonal antibodies

  • 100

    Three-part blood cell differential: erythrocytes, leukocytes, and platelets. A. Erythrocytes, leukocytes and platelets B. Monocytes, granulocytes, and lymphocytes C. Mononuclear cells, granulocytes, and lymphocytes D. Segmented neutrophils, eosinophils, and basophils

    C. Mononuclear cells, granulocytes, and lymphocytes

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    The growth factor that is produced in the kidney/liver and INDUCES GROWTH AND DIFFERENTIATION OF COMMITTED MEGAKARYOCYTE PROGENITORS is: A. IL-3 B. IL-6 C. IL-11 D. TPO

    D. TPO

  • 2

    Which of the following is (are) true of ENDOREDUPLICATION? A. Duplicates DNA without cell division B. Results in cells with ploidy values of 4n, 8n, 16n and 32n C. Is unique to the megakaryocytic type of blood cell D. All of the above

    D. All of the above

  • 3

    The megakaryocyte progenitor that undergoes endomitosis is: A. MK-I B. BFU-Meg C. CFU-Meg D. LD-CFU-Meg

    D. LD-CFU-Meg

  • 4

    The cellular ultrastructural component unique to the platelet is the: A. Cytoplasmic membrane B. Glycocalyx C. Mitochondrion D. Microtubule

    B. Glycocalyx

  • 5

    Which of the following is not a characteristic of platelets? A. The presence of a nucleus B. Size of 2 to 4 µm C. Cytoplasm is light blue with fine red-purple granules D. A discoid shape as an inactive cell

    A. The presence of a nucleus

  • 6

    Choose the INCORRECT statement regarding storage granules related to hemostasis in the mature platelet. A. Alpha granules contain platelet factor 4, betathromboglobulin, and platelet-derived growth factor. B. Alpha granules contain platelet fibrinogen and von Willebrand factor. C. Dense bodies contain serotonin n ADP. D. Lysosomes contain actomyosin, myosin, and flamin

    D. Lysosomes contain actomyosin, myosin, and flamin

  • 7

    Platelet aggregation will occur with the end production of: A. Cyclooxygenase B. Arachidonic acid C. Prostacyclin D. Thromboxane A2

    D. Thromboxane A2

  • 8

    Reticulated platelets can be enumerated in peripheral blood to detect: A. Impaired production in disease states B. Abnormal organelles associated with diseases such as leukemia C. Increased platelet production in response to need D. Inadequate rates of membrane cholesterol exchange with the plasma

    C. Increased platelet production in response to need

  • 9

    At all times, approximately ____ of the total number of platelets are in the systemic circulation. A. One-fourth B. One-third C. One-half D. Two-thirds

    D. Two-thirds

  • 10

    The reference range of platelets in the systemic circulation is: A. 50 to 120 x 109/L B. 100 to 200 x 109/L C. 150 to 350 x 109/L D. 150 to 400 x 109/L

    D. 150 to 400 x 109/L

  • 11

    Agents that are capable of aggregating platelets include: A. Collagen B. Thrombin C. Serotonin D. All of the above

    D. All of the above

  • 12

    In measuring platelet aggregation, platelet-rich plasma can be treated with ___ to aggregate platelets. A. Saline B. Collagen C. Epinephrine D. Both B and C

    D. Both B and C

  • 13

    What coagulation plasma protein should be assayed when platelets fail to aggregate properly? A. Factor VIII B. Fibrinogen C. Thrombin D. Factor X

    B. Fibrinogen

  • 14

    Aspirin ingestion has the following hemostatic effect in a normal person. A. Prolongs the bleeding time B. Prolongs the clotting time C. Inhibits factor VIII D. Has no effect

    A. Prolongs the bleeding time

  • 15

    The bleeding time test measures: A. Ability of platelets to stick together B. Platelet adhesion and aggregation of locally injured vascular subendothelium C. Quantity and quality of platelets D. Antibodies against platelets

    B. Platelet adhesion and aggregation of locally injured vascular subendothelium

  • 16

    The clot retraction test is: A. Visible reaction to the activation of platelet actomyosin (thrombosthenin) B. Reflection of the quantity and quality of platelets and other factors C. Measurement of the ability of platelets to stick to glass D. Measurement of the cloudiness of blood

    B. Reflection of the quantity and quality of platelets and other factors

  • 17

    Wiskott-Aldrich syndrome is characterized by: A. Giant platelets B. Smallest platelets seen C. Large platelets D. Absence of platelets

    B. Smallest platelets seen

  • 18

    May-Hegglin anomaly is characterized by: A. Giant platelets B. Smallest platelets seen C. Large platelets D. Absence of platelets

    C. Large platelets

  • 19

    Bernard-Soulier syndrome is characterized by: A. Giant platelets B. Smallest platelets seen C. Large platelets D. Absence of platelets

    A. Giant platelets

  • 20

    Hereditary platelet dysfunction can be caused by: A. Aspirin B. von Willebrand’s disease C. Uremia D. Factor V deficiency

    B. von Willebrand’s disease

  • 21

    Which of the following parameters can be abnormal in classic von Willebrand’s disease type I? A. Bleeding time B. PT C. Platelet count D. All of the above

    A. Bleeding time

  • 22

    The most common for of von Willebrand’s disease is: A. Type I B. Type II C. Type III D. All have about the same incidence

    A. Type I

  • 23

    When comparing von Willebrand’s disease and Glanzmann’s thrombasthenia, Glanzmann’s thrombasthenia will demonstrate: A. Absent ADP B. Normal clot retraction C. Abnormal ristocetin aggregation D. Abnormal release of ADP

    A. Absent ADP

  • 24

    Acquired platelet dysfunction can be caused by: A. Aspirin B. Von Willebrand’s disease C. Uremia D. Factor V deficiency

    C. Uremia

  • 25

    Thrombin: A. III B. XII C. VIII D. IIa

    D. IIa

  • 26

    Tissue thromboplastin: A. III B. XII C. VIII D. IIa

    A. III

  • 27

    Anti-hemophilic factor: A. III B. XII C. VIII D. IIa

    C. VIII

  • 28

    Hageman factor: A. III B. XII C. VIII D. IIa

    B. XII

  • 29

    The extrinsic pathway of coagulation is triggered by the entry of ___ into the circulation. A. Membrane lipoproteins (phospholipoproteins) B. Tissue thromboplastin C. Calcium D. Factor VII

    B. Tissue thromboplastin

  • 30

    The intrinsic pathway of coagulation begins with the activation of ____ in the early stage. A. Factor II B. Factor I C. Factor XII D. Factor V

    C. Factor XII

  • 31

    The final common pathway of the intrinsic-extrinsic pathway is: A. Factor X activation B. Factor II activation C. Factor I activation D. Factor XII activation

    A. Factor X activation

  • 32

    Fibrinogen is converted to thrombin monomers by: A. Prothrombin B. Thrombin C. Calcium ions D. Factor XIIIa

    B. Thrombin

  • 33

    The fibrinogen group of coagulation factors: A. Known to increase during pregnancy B. Known to increase in conditions of inflammation C. Known to increase subsequent to the use of oral contraceptives D. All of the above

    D. All of the above

  • 34

    A pregnant woman has routine coagulation testing performed. PT and APTT are normal. Her fibrinogen level is elevated at 450 (reference range 150 to 350) due to acute phase reactants during pregnancy. The other factor that may be elevated due to this is: A. FVII B. FVIII C. FXI D. FXIII

    B. FVIII

  • 35

    Vitamin K dependent coagulation factor: A. II B. V C. VIII D. XIII

    A. II

  • 36

    Unique characteristic associated with associated with a deficiency of Factor XII is: A. Frequent nose bleeds B. No history of bleeding C. Common factor deficiency D. Decreased risk of forming blood clots

    B. No history of bleeding

  • 37

    Factor XII deficiency is associated with: A. Bleeding episodes B. Epistaxis C. Decreased risk of thrombosis D. Increased risk of thrombosis

    D. Increased risk of thrombosis

  • 38

    What happens if a coagulation specimen collection tube is underfilled? A. The specimen clots and is useless B. The specimen is hemolyzed and is useless C. Clot-based test results are falsely prolonged D. Chromogenic test results are falsely decreased

    C. Clot-based test results are falsely prolonged

  • 39

    Most coagulation testing must be performed on PPP, which is plasma with a platelet count less than: A. 1000/µL B. 10,000/µL C. 100,000/µL D. 1,000,000/µL

    B. 10,000/µL

  • 40

    The function of thromboplastin in the prothrombin test is to provide _____ to the assay. A. Kaolin B. Fibrinogen C. Phospholipoprotein D. Thrombin

    C. Phospholipoprotein

  • 41

    An abnormally prolonged APTT may indicate: A. Severe depletion of fibrinogen B. Presence of circulating anticoagulant C. Factor VIII deficiency D. All of the above

    D. All of the above

  • 42

    Neither the APTT nor the PT detects a deficiency of: A. Platelet factor 3 B. Factor VII C. Factor VIII D. Factor IX

    A. Platelet factor 3

  • 43

    Which laboratory test is affected by heparin therapy? A. Thrombin time B. Fibrinogen assay C. Protein C assay D. Protein S assay

    A. Thrombin time

  • 44

    The test reagent in APTT contains which of the following substance(s)? 1. Citrated plasma 2. Calcium ions 3. Tissue thromboplastin 4. Phospholipids A. 1, 2 and 3 are correct B. 1 and 3 are correct C. 2 and 4 are correct D. Only 4 is correct

    C. 2 and 4 are correct

  • 45

    The test reagent in PT contains which of the following substance(s)? 1. Calcium ions 2. Kaolin 3. Tissue thromboplastin 4. Celite A. 1, 2 and 3 are correct B. 1 and 3 are correct C. 2 and 4 are correct D. Only 4 is correct

    B. 1 and 3 are correct

  • 46

    If a child ingested rat poison, which of the following tests should be performed to test the effect of the poison on the child’s coagulation mechanism? A. aPTT B. PT C. Fibrinogen assay D. Thrombin time

    B. PT

  • 47

    A patient on therapeutic warfarin will most likely have a(n): A. Normal PT/INR, increased APTT, prolonged bleeding time, low platelet count B. Increased PT/INR, increased APTT, normal bleeding time, normal platelet count C. Normal PT/INR, normal APTT, normal bleeding time, normal platelet count D. Increased PT/INR, normal APTT, prolonged bleeding time, low platelet count

    B. Increased PT/INR, increased APTT, normal bleeding time, normal platelet count

  • 48

    If heparin therapy is initiated in a patient, a decreased anticoagulant response can be caused by decreased levels of: A. Platelet factor 3 B. Platelet factor 4 C. Anti-thrombin D. Factor XIII

    B. Platelet factor 4 - TURGEON C. Anti-thrombin - RIGHT ANSWER

  • 49

    Heparin-induced thrombocytopenia (HIT) results from: A. Antibodies to heparin B. Antibodies to platelets C. Antibodies to PF4 D. Antibodies to heparin-PF4 complex

    D. Antibodies to heparin-PF4 complex

  • 50

    A modification of which procedure can be used to measure fibrinogen? A. PT B. APTT C. Thrombin time D. Fibrin degradation products

    C. Thrombin time

  • 51

    In the Clauss fibrinogen method, the time to clot formation in plasma is measured after the addition of: A. Calcium B. Thrombin C. Phospholipids D. Kaolin

    B. Thrombin

  • 52

    Which test result would be normal in a patient with dysfibrinogenemia? A. Thrombin time B. APTT C. PT D. Immunologic fibrinogen level

    D. Immunologic fibrinogen level

  • 53

    A standard blue-top tube filled appropriately (with 4.5 mL blood) was submitted to the laboratory for preoperative PT and APTT testing. The results of both tests were elevated. § The patient’s PT and APTT from the previous day were within normal limits, and he is not on heparin therapy. Which is the most appropriate first step to investigate the abnormal results? A. Report the result as obtained B. Perform a mixing study C. Check the sample for a clot D. Report the APTT only

    C. Check the sample for a clot

  • 54

    A fresh blood sample was sent to the laboratory at 8:00 a.m. for a PT test. At 4:00 p.m., the doctor requested an APTT test to be done on the same sample. What should the technologist do? A. Rerun APTT on the 8:00 a.m. sample and report the result B. Request a new sample for APTT C. Run APTT in duplicate and report the average D. Mix the patient plasma with normal plasma and run the APTT

    B. Request a new sample for APTT

  • 55

    A plasma sample submitted to the lab for PT testing has been stored for 25 hours at 4°C. The PT result is shortened. What is the most probable cause? A. Factor VII deficiency B. Activation of factor VII due to exposure to cold temperature C. Lupus inhibitor D. Factor X inhibitor

    B. Activation of factor VII due to exposure to cold temperature

  • 56

    An abnormal APTT caused by a pathological circulating anticoagulant is: A. Corrected with factor VIII–deficient plasma B. Corrected with factor IX–deficient plasma C. Corrected with normal plasma D. Not corrected with normal plasma

    D. Not corrected with normal plasma

  • 57

    Which of the following abnormalities is consistent with the presence of lupus anticoagulant? A. Decreased APTT/bleeding complications B. Prolonged APTT/thrombosis C. Prolonged APTT/thrombocytosis D. Thrombocytosis/thrombosis

    B. Prolonged APTT/thrombosis

  • 58

    What clotting factors (cofactors) are inhibited by protein S? A. V and X B. Va and VIIIa C. VIII and IX D. VIII and X

    B. Va and VIIIa

  • 59

    A THROMBOSIS MARKER that has shown high sensitivity for disseminated intravascular coagulation (DIC) is: A. Thrombin-antithrombin (TAT) B. Prothrombin fragment 1.2 (PF1.2) C. Fibrinopeptide A (FPA) D. D-dimer (D-D)

    D. D-dimer (D-D)

  • 60

    The APTT results are not elevated in a patient receiving heparin. Which of the following factors may be associated with the lack of response to heparin therapy in this patient? A. Protein C deficiency B. Antithrombin deficiency C. Protein S deficiency D. Factor VIII deficiency

    B. Antithrombin deficiency

  • 61

    Which of the following is the appropriate principle or description of the antithrombin assay? A. In the presence of heparin, thrombin is neutralized B. Measures the time required to generate thrombin and fibrin polymers via the intrinsic pathway C. Measures inhibitors of specific factors D. An in vivo measurement of platelet adhesion and aggregation on locally injured vascular subendothelium

    A. In the presence of heparin, thrombin is neutralized

  • 62

    . The FIRST step in the determination of functional antithrombin III (AT III) is to: A. Neutralize plasma antithrombin B. Neutralize thrombin with test plasma C. Incubate plasma with anti-AT III D. Precipitate AT III with plasma

    B. Neutralize thrombin with test plasma

  • 63

    Which of the following is considered to be an advantage of the mechanical end-point detection methodology? A. It is not affected by lipemia in the test sample B. It has the ability to provide a graph of clot formation C. It can incorporate multiple wavelengths into a single testing sequence D. It can measure proteins that do not have fibrin formation as the end-point

    A. It is not affected by lipemia in the test sample

  • 64

    The fibrometer relies on the principle of: A. Clot elasticity B. Fibrin adhesion C. Conduction or impedance of an electrical current by fibrin D. Changes in optical density

    C. Conduction or impedance of an electrical current by fibrin

  • 65

    In the photo-optical method, the change in light transmission versus the ____ is used to determine the activity of coagulant factors or stages. A. Amount of patient’s plasma B. Amount of test reagent C. Time D. Temperature

    C. Time

  • 66

    Which clinical or specimen condition will produce an increased PCV test result? A. Splenectomy B. Rouleaux formation C. Polycythemia D. Hemolytic anemia crisis

    C. Polycythemia

  • 67

    Which of the following blood specimen conditions would NOT cause a falsely elevated concentration with a manually performed cyanamethemoglobin determination? A. Lipemia B. Extremely elevated WBC count C. Hemoglobin S D. Hemoglobin F

    D. Hemoglobin F

  • 68

    If an MCHC result of 40 g/dL is discovered in a patient’s instrumentation printout, what is the possible cause? A. Increased RDW B. Hypochromic RBC C. Agglutinated RBCs D. Increased number of RBC fragments

    C. Agglutinated RBCs

  • 69

    What hematology test is useful in monitoring the production of erythrocytes? A. Total iron binding capacity B. Ferritin level C. Reticulocyte count D. Hemoglobin

    C. Reticulocyte count

  • 70

    On a Wright-stained peripheral blood smear, stress or shift reticulocytes are: A. Smaller than normal reticulocytes B. About the same size as normal reticulocytes C. Larger than normal reticulocytes D. Noticeable because of a decreased blue tint

    C. Larger than normal reticulocytes

  • 71

    Reticulocytes can be detected using ___ stain. A. New methylene blue B. Thiazole orange C. Propidium iodide D. Both A and B

    D. Both A and B

  • 72

    The normal range of reticulocytes in adults is: A. 0 to 0.5% B. 0.5 to 1% C. 0.5 to 2.5% D. 1.5 to 2.5%

    C. 0.5 to 2.5%

  • 73

    The refence value for reticulocyte count in a newborn infant is: A. Up to 13 mm per hour B. 2.5 to 6.5% C. 150 to 450 x 109 /L D. 36 to 45%

    B. 2.5 to 6.5%

  • 74

    What clinical or specimen condition will produce an increased reticulocyte count test result? A. Splenectomy B. Rouleaux formation C. Polycythemia D. Hemolytic anemia crisis

    D. Hemolytic anemia crisis

  • 75

    What clinical condition will produce a decreased reticulocyte count? A. Polycythemia vera B. Acute leukemias C. Megaloblastic anemia D. Viral infection

    C. Megaloblastic anemia

  • 76

    If a male patient has a reticulocyte count of 5.0% and a packed cell volume of 0.45 L/L, what is his corrected reticulocyte count? A. 2.5% B. 4.5% C. 5.0% D. 10%

    C. 5.0%

  • 77

    If a patient has a reticulocyte count of 7% and an Hct of 20%, what is the corrected reticulocyte count? A. 1.4% B. 3.1% C. 3.5% D. 14%

    B. 3.1%

  • 78

    If a male patient has a reticulocyte count of 6.0% and a packed cell volume of 45%, what is his RPI? A. 1.5 B. 3.0 C. 4.5 D. 6.0

    D. 6.0

  • 79

    Given the following values, calculate the RPI: § Observed reticulocyte count = 6% § HCT = 30% A. 2 B. 3 C. 4 D. 5

    A. 2

  • 80

    The ESR is a nonspecific indicator of disease with increased sedimentation of erythrocytes in: A. Infections B. Inflammations C. Tissue necrosis D. All of the above

    D. All of the above

  • 81

    The reference value for the Westergren ESR method for adult male less than 50 years of age is: A. 0 to 10 mm/hour B. 2.5 to 6.0% C. 150 to 450 x 109/L D. 36 to 35%

    A. 0 to 10 mm/hour

  • 82

    The reference value for the Westergren ESR method (adult male over 50 years) is: A. Up to 15 mm/hour B. 2.5 to 6% C. 150 to 450 x 109 /L D. 36 to 45%

    A. Up to 15 mm/hour

  • 83

    Which clinical or specimen condition will produce an increased Westergren ESR method test result? A. Splenectomy B. Rouleaux formation C. Polycythemia D. Hemolytic anemia crisis

    B. Rouleaux formation

  • 84

    Which clinical or specimen condition will produce an decreased Westergren ESR method test result? A. Polycythemia vera B. Acute leukemias C. Megaloblastic anemia D. Viral infection

    A. Polycythemia vera

  • 85

    What clinical or specimen condition will produce an increased total leukocyte count? A. Active allergies B. Immediate hypersensitivity reactions C. Inflammation D. Lipemic blood specimen

    C. Inflammation

  • 86

    What clinical condition will produce an increased value of neutrophils? A. Invasive parasites B. Bacterial infections C. Viral infections D. Tuberculosis

    B. Bacterial infections

  • 87

    What clinical condition will produce an increased value of eosinophils? A. Invasive parasites B. Bacterial infections C. Viral infections D. Tuberculosis

    A. Invasive parasites

  • 88

    What clinical condition will produce an increased value of lymphocytes? A. Invasive parasites B. Bacterial infections C. Viral infections D. Tuberculosis

    C. Viral infections

  • 89

    A normal blood smear should have no more than approximately ____ (maximum) number of platelets per OIF in an area where the erythrocytes are just touching each other. A. 10 B. 15 C. 20 D. 25

    C. 20

  • 90

    If small blood clot exists in an anticoagulated blood specimen, which blood cell parameter will be affected the most? A. Leukocyte count B. Erythrocyte count C. Platelet count D. Microhematocrit

    C. Platelet count

  • 91

    If platelet clumping was observed by direct observation of a stained peripheral blood smear and/or indicated by the output of an automated instrument, what corrective action can be taken? A. Retrieve the patient specimen and prepare a new blood smear B. Retrieve the patient specimen and warm it up to 37 o C for 15 minutes and reanalyze C. Recollect a new EDTA-anticoagulated specimen and promptly examine the platelets D. Recollect a new citrate anticoagulated specimen and reexamine the platelets.

    D. Recollect a new citrate anticoagulated specimen and reexamine the platelets

  • 92

    The recommended cleaner for removing oil from objectives is: A. 70% alcohol or lens cleaner B. Xylene C. Water D. Benzene

    A. 70% alcohol or lens cleaner

  • 93

    Which of the following is not a benefit of laboratory instrumentation to the hematology laboratory? A. Produces faster results from specimens B. Reduced cost on rarely performed procedures C. Less variation in technique from technologist to technologist D. Increased accuracy because data are collected on more cells counted or analyzed

    B. Reduced cost on rarely performed procedures

  • 94

    Sometimes used in conjunction with DC: A. Electronic impedance B. Optical scatter C. Radiofrequency D. None of these

    C. Radiofrequency

  • 95

    The abbreviation LASER stands for: A. Light associated stimulated emission of radiation B. Largely amplified by stimulated emission of radiation C. Light amplified by stimulated emission of radiation D. Liquid amplified by stimulated emission of radiation

    C. Light amplified by stimulated emission of radiation

  • 96

    Major systems in a flow cytometer include all of the following, EXCEPT: A. Fluidics B. Optics C. Computerized electronics D. Gating

    D. Gating

  • 97

    The restriction of data analysis to one cell population is accomplished by: A. Amplification B. Gating C. Compensatory monitoring D. Data limitation

    B. Gating

  • 98

    Which of the following can be an application of flow cytometry? A. Screening erythrocytes for malaria B. Counting reticulocytes C. Quantitation of T and B cells D. All of the above

    D. All of the above

  • 99

    The major application of flow cytometry is: A. Determining cell size and granularity B. Sorting of cells and cellular identification using monoclonal antibodies C. Treating cancer cells and identifying specific virus types D. Counting leukocytes and platelets

    B. Sorting of cells and cellular identification using monoclonal antibodies

  • 100

    Three-part blood cell differential: erythrocytes, leukocytes, and platelets. A. Erythrocytes, leukocytes and platelets B. Monocytes, granulocytes, and lymphocytes C. Mononuclear cells, granulocytes, and lymphocytes D. Segmented neutrophils, eosinophils, and basophils

    C. Mononuclear cells, granulocytes, and lymphocytes